Long title
An open-label phase I, multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease.
Date receipt dossier
EU record number
CYAD-211-001
EudraCT number
2020-001414-38
Company / Sponsor
Celyad
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
Multiple myeloma
Therapeutic approach
Immunotherapy
Genetic modification
BCMA-CAR and ShRNA CD3ζ
Method of transfer of nucleic acid of interest
Moloney murine leukemia virus
Administered biological material
Autologous T-cells retrovirally transduced with BCMA-CAR and ShRNA CD3ζ
Route of administration
Intravenous
Locations in Belgium
UZA, AZ Delta
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
CYAD-211